News & SEC Filings

View the latest news and SEC filings

News

LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call

RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company

Ohtuvayre TM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in

LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025: TD Cowen 45 th Annual Health Care Conference Date: Monday,

SEC Filings

Date Form Filing Group

March 28, 2025

Report of unscheduled material events or corporate event

8-K

Current Reports

March 18, 2025

An annual report to security holders

ARS

Annual Filings

March 18, 2025

Official notification to shareholders of matters to be brought to a vote (“Proxy”)

DEF 14A

Proxy Filings

March 13, 2025

Statement of changes in beneficial ownership of securities

4

3,4,5

March 12, 2025

Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

144

Other

February 28, 2025

Statement of changes in beneficial ownership of securities

4

3,4,5

February 27, 2025

Report of unscheduled material events or corporate event

8-K

Current Reports

February 27, 2025

Annual report which provides a comprehensive overview of the company for the past year

10-K

Annual Filings

February 27, 2025

Securities offered to employees pursuant to employee benefit plans

S-8

Registration Statements

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.